Australia markets open in 28 minutes

Allogene Therapeutics, Inc. (ALLO)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
10.88+0.26 (+2.45%)
At close: 04:00PM EDT
10.88 0.00 (0.00%)
After hours: 06:12PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close10.62
Open10.55
Bid10.50 x 2200
Ask12.23 x 3000
Day's range10.55 - 11.55
52-week range6.43 - 26.21
Volume2,681,314
Avg. volume1,655,474
Market cap1.565B
Beta (5Y monthly)0.52
PE ratio (TTM)N/A
EPS (TTM)N/A
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • GlobeNewswire

    Allogene Therapeutics Announces Participation in the Jefferies Cell and Genetic Medicine Summit

    SOUTH SAN FRANCISCO, Calif., Sept. 23, 2022 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer, today announced that management plans to present at the Jefferies Cell and Genetic Medicine Summit on Friday, September 30, 2022 at 6:30AM Pacific Time/9:30AM Eastern Time. The webcast will be posted to the Company's website at www.allogene.com under the Investors tab in

  • GlobeNewswire

    Allogene Therapeutics Reports Second Quarter 2022 Financial Results

    U.S. FDA Clearance on Potential Pivotal Phase 2 Trial of ALLO-501A Anticipated in Coming Weeks Expected to be the Industry’s First Allogeneic CAR T Phase 2 Pivotal TrialClearance to Cover ALPHA2 Protocol and Chemistry Manufacturing and Controls (CMC) for Use of ALLO-501A Manufactured from Cell Forge 1 (CF1)CF1 is Projected to Support the Manufacture of ~20,000 Doses of AlloCAR T™ Products Annually at Scale CF1 Earned a LEED® Interior Design and Construction Gold Designation from the U.S Green Bu

  • GlobeNewswire

    Allogene Therapeutics Announces Participation in Three Upcoming Investor Conferences

    SOUTH SAN FRANCISCO, Calif., Aug. 03, 2022 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer, today announced that management plans to participate in three upcoming investor conferences. 42nd Annual Canaccord Genuity Growth ConferenceThursday, August 11, 2022Noon PT/3:00PM ET H.C. Wainwright 24th Annual Global Investment ConferenceMonday, September 12, 2022Presenta